CBS 2019
CBSMD教育中心
中 文

药物涂层球囊

Abstract

Recommended Article

Comparison of 2 Different Drug-Coated Balloons in In-Stent Restenosis: The RESTORE ISR China Randomized Trial Long-term clinical outcomes after treatment of stent restenosis with two drug-coated balloons Drug-Coated Balloon for De Novo Coronary Artery Disease: JACC State-of-the-Art Review Percutaneous Treatment and Outcomes of Small Coronary Vessels: A SCAAR Report Benefits with drug-coated balloon as compared to a conventional revascularization strategy for the treatment of coronary and non-coronary arterial disease: a comprehensive meta-analysis of 45 randomized trials 3-Year Clinical Follow-Up of the RIBS IV Clinical Trial A Prospective Randomized Study of Drug-Eluting Balloons Versus Everolimus-Eluting Stents in Patients With In-Stent Restenosis in Coronary Arteries Previously Treated With Drug-Eluting Stents Survival After Coronary Revascularization With Paclitaxel-Coated Balloons Drug-Coated Balloon Angioplasty Versus Drug-Eluting Stent Implantation in Patients With Coronary Stent Restenosis
|<< 1 2 3 4 5 6 >>|

Review ArticleVolume 71, Issue 14, April 2018

JOURNAL：J Am Coll Cardio. Article Link

Respiratory Syncytial Virus and Associations With Cardiovascular Disease in Adults

KS Ivey, KM Edwards, HK Talbot et al. Keywords: cardiac exacerbation; hospitalizations; respiratory syncytial virus

ABSTRACT

Respiratory syncytial virus (RSV) is historically known for causing respiratory illness in young children, but the appreciation of its impact on older adults is growing. Studies have shown that hospitalization for respiratory illness due to RSV is complicated by cardiovascular events in 14% to 22% of adult patients, including worsening congestive heart failure, acute coronary syndrome, and arrhythmias. Additionally, underlying cardiovascular disease is associated with hospitalization in 45% to 63% of adults with confirmed RSV. In summary, patients with cardiopulmonary disease have higher rates of health care utilization for RSV-related illness and worse outcomes. Patients with cardiovascular disease likely represent an important target population for the rapidly developing field of RSV vaccines.

>CBS CBS 2019

> CBS 2019 REGISTRATION

> CBS 2019 PROGRAM

> CBS 2019 CALL FOR SCIENCE

> CBS 2019 SPOTLIGHTS

 CBSMD

> CBSMD WEBSITE REGISTRATION

> EDUCATION CENTER

> RECOMMANDED PAPER

> TOP 10 RESEARCH PAPER

> PRE-READING

CBS 2019 CBS 2019 FACULTY Education Resource CBSMD Scientific Library
Copyright ⓒ CBS MD Nanjing China. All rights reserved. 京ICP备16025898号-11
联系我们| Top